4/22
04:05 pm
rna
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/18
05:01 pm
rna
FYBR, BCRX and SABR are among after hour movers [Seeking Alpha]
Low
Report
FYBR, BCRX and SABR are among after hour movers [Seeking Alpha]
4/11
08:06 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
Low
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
3/27
09:00 am
rna
Avidity Biosciences to Participate in Upcoming Investor Conferences
Low
Report
Avidity Biosciences to Participate in Upcoming Investor Conferences
3/21
04:05 pm
rna
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/14
08:30 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $60.00 price target on the stock.
Medium
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $60.00 price target on the stock.
3/5
01:58 pm
rna
Avidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Data [Seeking Alpha]
Low
Report
Avidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Data [Seeking Alpha]
3/4
07:17 am
rna
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial [Yahoo! Finance]
Medium
Report
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial [Yahoo! Finance]
3/4
07:00 am
rna
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
High
Report
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
3/1
07:07 am
rna
Avidity Biosciences Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
Medium
Report
Avidity Biosciences Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
2/29
12:16 pm
rna
Avidity Biosciences Honors Rare Disease Day® [Yahoo! Finance]
Low
Report
Avidity Biosciences Honors Rare Disease Day® [Yahoo! Finance]
2/29
12:00 pm
rna
Avidity Biosciences Honors Rare Disease Day®
Low
Report
Avidity Biosciences Honors Rare Disease Day®
2/29
09:10 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
Low
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
2/29
08:16 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $23.00 price target on the stock.
Low
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $23.00 price target on the stock.
2/29
07:23 am
rna
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement [Yahoo! Finance]
Low
Report
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement [Yahoo! Finance]
2/29
07:00 am
rna
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
Medium
Report
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
2/28
06:32 pm
rna
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
High
Report
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
2/28
04:13 pm
rna
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights [Yahoo! Finance]
High
Report
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights [Yahoo! Finance]
2/28
04:05 pm
rna
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
High
Report
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
2/27
09:00 am
rna
Avidity Biosciences to Participate in Upcoming Investor Conferences
Medium
Report
Avidity Biosciences to Participate in Upcoming Investor Conferences
2/21
04:05 pm
rna
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/20
09:18 am
rna
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping [Yahoo! Finance]
Low
Report
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping [Yahoo! Finance]
2/20
09:00 am
rna
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Medium
Report
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
2/15
05:08 pm
rna
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference [Yahoo! Finance]
Medium
Report
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference [Yahoo! Finance]
2/15
05:00 pm
rna
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Low
Report
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference